drugset / Trial / NCT01287598
BAY73-4506 Probe Substrate Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
* To evaluate the effect of BAY73-4506 on the pharmacokinetics of probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) administered in a cocktail approach and on the pharmacokinetics of a probe substrate of CYP 2C8 (rosiglitazone) * To evaluate safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of BAY73-4506 in patients with advanced solid tumors
Timeline
- Start
- 2011-08-02
- Primary completion
- 2018-07-03
- Completion
- 2018-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midazolam | Small molecule | — | — |
| Subject | Omeprazole | Other / unclassified | — | — |
| Subject | Regorafenib | Small molecule | — | — |
| Subject | Rosiglitazone | Small molecule | — | — |
| Subject | Warfarin | Small molecule | — | — |